ChemoMetec A/S (FRA:CHY)

Market Cap	1.42B +19.0%
Revenue (ttm)	66.43M +21.5%
Net Income	24.99M +36.8%
EPS	1.44 +36.8%
Shares Out	n/a
PE Ratio	56.83
Forward PE	43.03
Dividend	0.94 (1.00%)
Ex-Dividend Date	Oct 10, 2025

Volume	n/a
Average Volume	14
Open	88.50
Previous Close	88.95
Day's Range	84.90 - 88.50
52-Week Range	51.90 - 106.60
Beta	n/a
RSI	26.70
Earnings Date	Feb 4, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 170
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CHY

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK